Thomas A. Hensing

4.3k total citations
83 papers, 2.9k citations indexed

About

Thomas A. Hensing is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Thomas A. Hensing has authored 83 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pulmonary and Respiratory Medicine, 55 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Thomas A. Hensing's work include Lung Cancer Treatments and Mutations (55 papers), Lung Cancer Diagnosis and Treatment (31 papers) and Lung Cancer Research Studies (28 papers). Thomas A. Hensing is often cited by papers focused on Lung Cancer Treatments and Mutations (55 papers), Lung Cancer Diagnosis and Treatment (31 papers) and Lung Cancer Research Studies (28 papers). Thomas A. Hensing collaborates with scholars based in United States, Canada and South Korea. Thomas A. Hensing's co-authors include Mark A. Socinski, Ravi Salgia, Daniel B. Fried, David E. Morris, Rogério Lilenbaum, Jyoti D. Patel, Frank C. Detterbeck, Thomas E. Stinchcombe, Julian Rosenman and Jan Halle and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Thomas A. Hensing

83 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas A. Hensing United States 26 1.7k 1.6k 670 365 317 83 2.9k
Domenico Galetta Italy 28 1.3k 0.8× 1.5k 0.9× 374 0.6× 352 1.0× 245 0.8× 175 2.8k
Bryan J. Schneider United States 26 1.6k 1.0× 1.2k 0.8× 613 0.9× 540 1.5× 334 1.1× 75 2.8k
Jens Benn Sørensen Denmark 35 1.9k 1.1× 2.4k 1.5× 932 1.4× 320 0.9× 487 1.5× 143 4.0k
Anne M. Traynor United States 32 1.3k 0.8× 1.1k 0.7× 933 1.4× 139 0.4× 293 0.9× 117 2.9k
Paolo Maione Italy 31 2.2k 1.3× 2.0k 1.3× 1.1k 1.6× 233 0.6× 452 1.4× 138 3.6k
Janessa Laskin Canada 30 2.2k 1.3× 2.1k 1.3× 1.0k 1.6× 288 0.8× 774 2.4× 187 3.8k
Tracey L. Evans United States 29 2.1k 1.3× 2.1k 1.3× 933 1.4× 509 1.4× 583 1.8× 107 4.0k
Anne C. Chiang United States 19 1.9k 1.1× 1.2k 0.8× 1.1k 1.7× 227 0.6× 682 2.2× 88 3.1k
Meghan J. Mooradian United States 19 1.8k 1.1× 1.2k 0.7× 472 0.7× 256 0.7× 282 0.9× 68 2.6k
Purvish M. Parikh India 21 2.6k 1.5× 2.6k 1.6× 952 1.4× 196 0.5× 587 1.9× 160 4.4k

Countries citing papers authored by Thomas A. Hensing

Since Specialization
Citations

This map shows the geographic impact of Thomas A. Hensing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Hensing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Hensing more than expected).

Fields of papers citing papers by Thomas A. Hensing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Hensing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Hensing. The network helps show where Thomas A. Hensing may publish in the future.

Co-authorship network of co-authors of Thomas A. Hensing

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Hensing. A scholar is included among the top collaborators of Thomas A. Hensing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Hensing. Thomas A. Hensing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Krantz, Seth B., Kristine Kuchta, Thomas A. Hensing, et al.. (2022). Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non–small cell lung cancer. JTCVS Open. 12. 399–409. 2 indexed citations
2.
Olugbile, Sope, Riyue Bao, Thomas A. Hensing, Yusuke Nakamura, & Everett E. Vokes. (2017). MA15.07 Molecular Determinants of Lack of Tumor Immune Infiltration in NSCLC. Journal of Thoracic Oncology. 12(1). S431–S432. 2 indexed citations
3.
Tan, Yi‐Hung Carol, et al.. (2016). The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative. Cureus. 8(3). e533–e533. 3 indexed citations
4.
Campbell, Nicholas, Thomas A. Hensing, Mihir K. Bhayani, Arif Y. Shaikh, & Bruce Brockstein. (2016). Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy. 16(8). 847–858. 6 indexed citations
5.
6.
Yount, Susan, Jennifer L. Beaumont, Sarah Rosenbloom, et al.. (2011). A Brief Symptom Index for Advanced Lung Cancer. Clinical Lung Cancer. 13(1). 14–23. 22 indexed citations
7.
Stinchcombe, Thomas E., Amy H. Peterman, Carrie B. Lee, et al.. (2011). A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(9). 1569–1577. 30 indexed citations
8.
Salgia, Ravi, Thomas A. Hensing, Nicholas Campbell, et al.. (2011). Personalized Treatment of Lung Cancer. Seminars in Oncology. 38(2). 274–283. 34 indexed citations
9.
Roy, Hemant K., Hariharan Subramanian, Dhwanil Damania, et al.. (2010). Optical Detection of Buccal Epithelial Nanoarchitectural Alterations in Patients Harboring Lung Cancer: Implications for Screening. Cancer Research. 70(20). 7748–7754. 47 indexed citations
10.
Eilers, Robert, Mona A. Gandhi, Jyoti D. Patel, et al.. (2009). Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy. JNCI Journal of the National Cancer Institute. 102(1). 47–53. 122 indexed citations
11.
Cella, David, David T. Eton, Thomas A. Hensing, Gregory A. Masters, & Bhash Parasuraman. (2008). Relationship Between Symptom Change, Objective Tumor Measurements, and Performance Status During Chemotherapy for Advanced Lung Cancer. Clinical Lung Cancer. 9(1). 51–58. 14 indexed citations
12.
Stinchcombe, Thomas E., Harry Harper, Thomas A. Hensing, et al.. (2008). The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(2). 145–151. 10 indexed citations
13.
Stinchcombe, Thomas E., Daniel B. Fried, Maria Q. Baggstrom, Thomas A. Hensing, & Mark A. Socinski. (2008). Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis. Journal of Thoracic Oncology. 3(3). 320–322. 11 indexed citations
14.
Lilenbaum, Rogério, John Cashy, Thomas A. Hensing, Susan E. Young, & David Cella. (2008). Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research. Journal of Thoracic Oncology. 3(2). 125–129. 164 indexed citations
15.
Baggstrom, Maria Q., Thomas E. Stinchcombe, Daniel B. Fried, et al.. (2007). Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis. Journal of Thoracic Oncology. 2(9). 845–853. 98 indexed citations
16.
Govindan, Ramaswamy, Ronald B. Natale, James L. Wade, et al.. (2006). Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 53(3). 331–337. 9 indexed citations
17.
Hoang, Tien, KyungMann Kim, Anne M. Traynor, et al.. (2006). Phase I/II Study of Gemcitabine and Exisulind as Second-Line Therapy in Patients with Advanced Non–small Cell Lung Cancer. Journal of Thoracic Oncology. 1(3). 218–225. 6 indexed citations
18.
Socinski, Mark A., Anastasia Ivanova, J. Gerard Wall, et al.. (2005). A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Annals of Oncology. 17(1). 104–109. 34 indexed citations
19.
Hensing, Thomas A.. (2005). Clinical Evaluation and Staging of Patients Who Have Lung Cancer. Hematology/Oncology Clinics of North America. 19(2). 219–235. 8 indexed citations
20.
Hensing, Thomas A., Amy H. Peterman, Michael J. Schell, Ji‐Hyun Lee, & Mark A. Socinski. (2003). The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 98(4). 779–788. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Domenico Galetta Breakdown of academic impact, for papers by Bryan J. Schneider Breakdown of academic impact, for papers by Jens Benn Sørensen Breakdown of academic impact, for papers by Anne M. Traynor Breakdown of academic impact, for papers by Paolo Maione Breakdown of academic impact, for papers by Janessa Laskin Breakdown of academic impact, for papers by Tracey L. Evans Breakdown of academic impact, for papers by Anne C. Chiang Breakdown of academic impact, for papers by Meghan J. Mooradian Breakdown of academic impact, for papers by Purvish M. Parikh
Rankless by CCL
2026